Gabelli analyst Kevin Kedra reiterated a Buy rating on Collegium Pharmaceutical (NASDAQ: COLL).The analyst comments "We continue to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE